A pharmacist receives a new prescription. The prescription reads:
Bydureon 2mg SC every day for type II diabetes x 30 days.
Refill: 5 times
Which of the following is the most appropriate action by a pharmacist?
a. Fill as it is.
b. Question the physician about the indication of the drug.
c. Question the physician about the refill quantity of the drug.
d. Question the physician about the dosage frequency of the drug.
e. Question the physician about the dosage strength of the drug.
Answer:(d). The active ingredient found in Bydureon is Exenatide indicated for the treatment of type II diabetes mellitus. It is an incretin mimetic agent. Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. Bydureon is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying.
Bydureon is an extended-release formulation of Exenatide, administered as an injection once every 7 days (weekly). It is also available under the trade name Byetta. Byetta is an immediate release solution of Exenatide administered by SC route. Byetta should be initiated at 5 mcg administered twice daily at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart).
Nausea, vomiting, diarrhea, dyspepsia, injection site reactions, constipation and hypoglycemia are commonly reported side effects of Bydureon.
Try Naplex QBank. www.pharmacyexam.com